别名 硫氧还蛋白类、ADF、Allergen: + [10] |
简介 ADF augments the expression of the interleukin-2 receptor TAC (IL2R/P55).
Participates in various redox reactions through the reversible oxidation of its active center dithiol to a disulfide and catalyzes dithiol-disulfide exchange reactions (PubMed:2176490, PubMed:17182577, PubMed:19032234). Plays a role in the reversible S-nitrosylation of cysteine residues in target proteins, and thereby contributes to the response to intracellular nitric oxide. Nitrosylates the active site Cys of CASP3 in response to nitric oxide (NO), and thereby inhibits caspase-3 activity (PubMed:16408020, PubMed:17606900). Induces the FOS/JUN AP-1 DNA-binding activity in ionizing radiation (IR) cells through its oxidation/reduction status and stimulates AP-1 transcriptional activity (PubMed:9108029, PubMed:11118054). |
作用机制 GLRX调节剂 [+1] |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 TXN抑制剂 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 TXN刺激剂 |
在研机构- |
原研机构 |
在研适应症- |
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2022-08-12 |
申办/合作机构 |
开始日期2010-04-01 |
申办/合作机构 |
开始日期2004-08-01 |
申办/合作机构 |